We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+14.94%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$112M
AUM Growth
+$11.4M
Cap. Flow
-$5.75M
Cap. Flow %
-5.12%
Top 10 Hldgs %
46.21%
Holding
94
New
5
Increased
13
Reduced
15
Closed
17

Top Buys

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.27M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$3.99M
3
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$1.68M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.45M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.34M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$4.35M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$2.22M
3
OTIC
Otonomy, Inc.
OTIC
+$1.99M
4
XNPT
XENOPORT, INC.
XNPT
+$1.63M
5
PLX icon
Protalix BioTherapeutics
PLX
+$1.41M

Sector Composition

Rank Sector Weight
1 Healthcare 76.52%
2 Financials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDQ
26
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.3M 1.16%
101,841
– –
SPNC
27
DELISTED
Spectranetics Corp
SPNC
$1.2M 1.07%
79,812
– –
EPIX
28
DELISTED
ESSA Pharma
EPIX
$1.04M 0.93%
11,425
– –
ZGNX
29
DELISTED
Zogenix, Inc.
ZGNX
$1.02M 0.91%
69,400
+500
+0.7% +$6.72K
STXS icon
30
Stereotaxis
STXS
$133M
$1.02M 0.91%
1,372,862
– –
ASND icon
31
Ascendis Pharma A/S
ASND
$16.5B
$975K 0.87%
53,241
– –
SCYX icon
32
SCYNEXIS
SCYX
$37M
$974K 0.87%
1,961
– –
JNJ icon
33
Johnson & Johnson
JNJ
$617B
$966K 0.86%
9,400
– –
NEOS
34
DELISTED
Neos Therapeutics, Inc
NEOS
$908K 0.81%
63,400
– –
CDNA icon
35
CareDx
CDNA
$1.97B
$871K 0.78%
136,047
+120
+0.1% +$653
XENE icon
36
Xenon Pharmaceuticals
XENE
$6.2B
$786K 0.7%
97,730
+72,730
+291% +$623K
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$785K 0.7%
750
– –
MGNX icon
38
MacroGenics
MGNX
$240M
$743K 0.66%
24,000
– –
ARNA
39
DELISTED
Arena Pharmaceuticals Inc
ARNA
$725K 0.65%
38,160
– –
CYNA
40
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$722K 0.64%
46,629
+1,805
+4% +$27.4K
ELOS
41
DELISTED
Syneron Medical Ltd
ELOS
$663K 0.59%
85,947
– –
LPCN icon
42
Lipocine
LPCN
$17.4M
$647K 0.58%
2,941
+294
+11% +$61.7K
INDP icon
43
Indaptus Therapeutics
INDP
$192M
$639K 0.57%
53
-7
-12% -$89.9K
ABEO icon
44
Abeona Therapeutics
ABEO
$369M
$611K 0.54%
7,273
– –
ALDR
45
DELISTED
Alder Biopharmaceuticals
ALDR
$595K 0.53%
18,000
– –
ADAP
46
DELISTED
Adaptimmune Therapeutics
ADAP
$580K 0.52%
+48,100
New +$471K
QURE icon
47
uniQure
QURE
$2.93B
$579K 0.52%
35,000
– –
EXAC
48
DELISTED
Exactech Inc
EXAC
$574K 0.51%
31,636
– –
VTVT icon
49
vTv Therapeutics
VTVT
$129M
$497K 0.44%
1,825
-50
-3% -$14K
FOMX
50
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$493K 0.44%
+60,770
New +$454K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, DAFNA Capital Management held 94 positions worth $112M, up 11% from $101M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management withdrew a net $5.75M in Q4 2015, closing 17 positions and reducing 15 holdings. Its most notable exit was ZS PHARMA INC COMS TK (DE), an estimated $4.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in CTI BioPharma Corp. (DE) Common Stock worth $3.93M.

  • DAFNA Capital Management's largest Q4 2015 buy was CTI BioPharma Corp. (DE) Common Stock: 319,538 shares worth $3.93M.
  • DAFNA Capital Management added most to Marinus Pharmaceuticals, Inc in Q4 2015, an estimated $3.99M increase.
  • DAFNA Capital Management's biggest Q4 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $2.22M.
  • DAFNA Capital Management fully exited ZS PHARMA INC COMS TK (DE) in Q4 2015, selling an estimated $4.35M.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $112M portfolio in Q4 2015.
  • DAFNA Capital Management opened 5 new positions and closed 17 in Q4 2015.
  • DAFNA Capital Management's portfolio value rose 11% quarter-over-quarter to $112M.

Based on DAFNA Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.